Medtronic (MDT) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Medtronic (MDT)

MDT 90.41

0.0%

Nov 5 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Dennis who wrote (550)	10/2/2001 1:51:19 PM
From: Jack Hartmann	Read Replies (1) of 687

GS on MDT today Medtronic, Inc., Guidant Corp. EPS (FY Apr): 2002E US$1.22, 2003E US$1.43 Recommended List Medtronic, Inc. MDT, $44.00 EPS (FY Dec): 2001E US$1.67, 2002E US$1.91 Market Performer Guidant Corp. GDT, $38.90 Third quarter stent market dynamics appear to be generally consistent with our expectations. However, we do note that revenues for J&J may modestly exceed our estimate based on momentum from the RX Velocity and continued popularity of the premium-priced Hepacoat. Subsequently, Boston Scientific' s position may be slightly weaker and Guidant may not have gained as much as projected in our model. Aggressive buying ahead of the injunction on RX product sales should enable Medtronic to meet our expectations for the quarter. We expect Guidant and J&J to be the primary beneficiaries of Medtronic' s lost RX sales, since Boston Scientific will not have a competitive product for nearly a year. Jack

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next